|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Groot JW, Links TP, Plukker JT, Lips CJ
and Hofstra RM: RET as a diagnostic and therapeutic target in
sporadic and hereditary endocrine tumors. Endocr Rev. 27:535–560.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kondo T, Ezzat S and Asa SL: Pathogenetic
mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer.
6:292–306. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smallridge RC, Marlow LA and Copland JA:
Anaplastic thyroid cancer: Molecular pathogenesis and emerging
therapies. Endocr Relat Cancer. 16:17–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ivan M, Bond JA, Prat M, Comoglio PM and
Wynford-Thomas D: Activated ras and ret oncogenes induce
over-expression of c-met (hepatocyte growth factor receptor) in
human thyroid epithelial cells. Oncogene. 14:2417–2423. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Salvatore D, Barone MV, Salvatore G,
Melillo RM, Chiappetta G, Mineo A, Fenzi G, Vecchio G, Fusco A and
Santoro M: Tyrosines 1015 and 1062 are in vivo autophosphorylation
sites in ret and ret-derived oncoproteins. J Clin Endocrinol Metab.
85:3898–3907. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Portella G, Vitagliano D, Borselli C,
Melillo RM, Salvatore D, Rothstein JL, Vecchio G, Fusco A and
Santoro M: Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a
thyroglobulin promoter, differently affect the expression of
differentiation markers and the proliferation of thyroid epithelial
cells. Oncol Res. 11:421–427. 1999.PubMed/NCBI
|
|
9
|
Jhiang SM, Sagartz JE, Tong Q,
Parker-Thornburg J, Capen CC, Cho JY, Xing S and Ledent C: Targeted
expression of the ret/PTC1 oncogene induces papillary thyroid
carcinomas. Endocrinology. 137:375–378. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Patrawala L, Calhoun T,
Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra
D, Zhou J, Claypool K, et al: Highly purified CD44+ prostate cancer
cells from xenograft human tumors are enriched in tumorigenic and
metastatic progenitor cells. Oncogene. 25:1696–1708. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matsui W, Huff CA, Wang Q, Malehorn MT,
Barber J, Tanhehco Y, Smith BD, Civin CI and Jones RJ:
Characterization of clonogenic multiple myeloma cells. Blood.
103:2332–2336. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dalerba P and Clarke MF: Cancer stem cells
and tumor metastasis: First steps into uncharted territory. Cell
Stem Cell. 1:241–242. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schatton T, Murphy GF, Frank NY, Yamaura
K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM,
Weishaupt C, et al: Identification of cells initiating human
melanomas. Nature. 451:345–349. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De
Maria R: Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ. 15:504–514. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Todaro M, Iovino F, Eterno V, Cammareri P,
Gambara G, Espina V, Gulotta G, Dieli F, Giordano S, De Maria R and
Stassi G: Tumorigenic and metastatic activity of human thyroid
cancer stem cells. Cancer Res. 70:8874–8885. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gascoigne KE and Taylor SS: How do
anti-mitotic drugs kill cancer cells? J Cell Sci. 122:2579–2585.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Forte S, Pagliuca A, Maniscalchi ET,
Gulino R, Calabrese G, Ricci-Vitiani L, Pallini R, Signore M,
Parenti R, De Maria R and Gulisano M: Gene expression analysis of
PTEN positive glioblastoma stem cells identifies DUB3 and Wee1
modulation in a cell differentiation model. PLoS One. 8:e814322013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ke CC, Liu RS, Yang AH, Liu CS, Chi CW,
Tseng LM, Tsai YF, Ho JH, Lee CH and Lee OK: CD-133-expressing
thyroid cancer cells are undifferentiated, radioresistant and
survive radioiodide therapy. Eur J Nucl Mol Imaging. 40:61–71.
2013. View Article : Google Scholar
|
|
23
|
Okano H, Kawahara H, Toriya M, Nakao K,
Shibata S and Imai T: Function of RNA-binding protein Musashi-1 in
stem cells. Exp Cell Res. 306:349–356. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sutherland JM, McLaughlin EA, Hime GR and
Siddall NA: The Musashi family of RNA binding proteins: Master
regulators of multiple stem cell populations. Adv Exp Med Biol.
786:233–245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eramo A, Ricci-Vitiani L, Zeuner A,
Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C and
De Maria R: Chemotherapy resistance of glioblastoma stem cells.
Cell Death Differ. 13:1238–1241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Portugal J, Bataller M and Mansilla S:
Cell death pathways in response to antitumor therapy. Tumori.
95:409–421. 2009.PubMed/NCBI
|
|
28
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem cells in
glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shafee N, Smith CR, Wei S, Kim Y, Mills
GB, Hortobagyi GN, Stanbridge EJ and Lee EY: Cancer stem cells
contribute to cisplatin resistance in Brca1/p53-mediated mouse
mammary tumors. Cancer Res. 68:3243–3250. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu L, McArthur C and Jaffe RB: Ovarian
cancer stem-like side-population cells are tumourigenic and
chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu T, Xu F, Du X, Lai D, Liu T, Zhao Y,
Huang Q, Jiang L, Huang W, Cheng W and Liu Z: Establishment and
characterization of multi-drug resistant, prostate
carcinoma-initiating stem-like cells from human prostate cancer
cell lines 22RV1. Mol Cell Biochem. 340:265–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wilson A, Laurenti E, Oser G, van der Wath
RC, Blanco-Bose W, Jaworski M, Offner S, Dunant CF, Eshkind L,
Bockamp E, et al: Hematopoietic stem cells reversibly switch from
dormancy to self-renewal during homeostasis and repair. Cell.
135:1118–1129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pece S, Tosoni D, Confalonieri S, Mazzarol
G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG and Di Fiore
PP: Biological and molecular heterogeneity of breast cancers
correlates with their cancer stem cell content. Cell. 140:62–73.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chonghaile Ni T, Sarosiek KA, Vo TT, Ryan
JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P,
Tai YT, et al: Pretreatment mitochondrial priming correlates with
clinical response to cytotoxic chemotherapy. Science.
334:1129–1133. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bettaieb A, Dubrez-Daloz L, Launay S,
Plenchette S, Rébé C, Cathelin S and Solary E: Bcl-2 proteins:
Targets and tools for chemosensitisation of tumor cells. Curr Med
Chem Anticancer Agents. 3:307–318. 2003. View Article : Google Scholar : PubMed/NCBI
|
